Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewLSN 2463359 is a potent and selective positive allosteric modulator at the mGlu5 receptor (EC50 = 24 nM). Has no activity at mGlu1-4, mGlu8 and GABAB receptors. Reverses methylazoxymethanol acetate (MAM)-induced deficits in reversal learning memory and normalizes SDZ 220-581 and RO 63-1908-induced alterations in instrumental responses in rat models. Promotes wakefulness in vivo. Brain penetrant and orally active.
M. Wt | 265.31 |
Formula | C16H15N3O |
Storage | Store at +4°C |
Purity | ≥99% (HPLC) |
CAS Number | 1401031-52-4 |
PubChem ID | 72551298 |
InChI Key | STAFRSGTRKNXHF-UHFFFAOYSA-N |
Smiles | O=C(NC(C)C)C(C=C2)=NC=C2C#CC1=CC=NC=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 26.53 | 100 | |
ethanol | 5.31 | 20 |
The following data is based on the product molecular weight 265.31. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.77 mL | 18.85 mL | 37.69 mL |
5 mM | 0.75 mL | 3.77 mL | 7.54 mL |
10 mM | 0.38 mL | 1.88 mL | 3.77 mL |
50 mM | 0.08 mL | 0.38 mL | 0.75 mL |
References are publications that support the biological activity of the product.
Gastambide et al (2012) Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator. Neuropsychopharmacology 37 1057 PMID: 22129780
Gilmour et al (2013) In vitro characterisation of the novel positive allosteric modulators of the mGlu5 receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology 64 224 PMID: 22884720
Gastambide et al (2013) The mGlu5 positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat. Neuropharmacology 64 240 PMID: 22884612
If you know of a relevant reference for LSN 2463359, please let us know.
View all Glutamate (Metabotropic) Group I Receptor Modulators
Keywords: LSN 2463359, LSN 2463359 supplier, LSN2463359, potent, selective, positive, allosteric, modulator, PAM, MGLU5, brain, penetrant, orally, active, schizophrenia, Glutamate, (Metabotropic), Group, I, Receptors, 5275, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for LSN 2463359. Do you know of a great paper that uses LSN 2463359 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review LSN 2463359 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.